Yang Cao^*, Xu Shi^†, Yingmin Liu^‡, Ren Xu^§, Qing Ai^*

Oncology Research, Vol.27, No.1, pp. 117-124, 2019, DOI:10.3727/096504018X15213031799835

Abstract MicroRNA-338-3p (miR-338-3p) has been reported to be a tumor suppressor in multiple cancer types. However, the biological role of miR-338-3p and its underlying mechanism in multiple myeloma (MM) remain unclear. In the present study, we investigated the biological role and potential of miR-338-3p in MM. We found that miR-338-3p was significantly decreased in newly diagnosed and relapsed MM tissues and cell lines. Overexpression of miR-338-3p in MM cells significantly inhibited proliferation and promoted apoptosis, caspase 3, and caspase 8 activity. Bioinformatics algorithm analysis predicted that cyclin-dependent kinase 4 (CDK4) was a direct target of miR-338-3p, and this was experimentally verified… More >

Yulong Jin^*, Li Xu^*, Xiaodong Wu^†, Juan Feng^*, Mimi Shu^*, Hongtao Gu^*, Guangxun Gao^*, Jinyi Zhang^‡, Baoxia Dong^*, Xiequn Chen^*

Oncology Research, Vol.27, No.6, pp. 729-737, 2019, DOI:10.3727/096504018X15443011011637

Abstract Multiple myeloma (MM) is a hematopoietic malignancy characterized by the clonal proliferation of antibodysecreting plasma cells. Bortezomib (BZM), the first FDA-approved proteasome inhibitor, has significant antimyeloma activity and prolongs the median survival of MM patients. However, MM remains incurable predominantly due to acquired drug resistance and disease relapse. -Catenin, a key effector protein in the canonical Wnt signaling pathway, has been implicated in regulating myeloma cell sensitivity to BZM. Decitabine (DAC) is an epigenetic modulating agent that induces tumor suppressor gene reexpression based on its gene-specific DNA hypomethylation. DAC has been implicated in modulating Wnt/ -catenin signaling by promoting the… More >